Health · Pharma & Biotech · 2 hrs ago

Oral deucrictibant reduced hereditary angioedema attacks in a phase III trial

Oral deucrictibant reduced hereditary angioedema attacks in a phase III trial

A pivotal phase III trial found that oral deucrictibant substantially reduced HAE attacks when used to prevent them.

HAE is short for hereditary angioedema.

Deucrictibant is a bradykinin B2 receptor antagonist, and the trial tested an extended-release version.

The study was described as a pivotal trial, a major step in evaluating a medicine.

Its results put the new oral option alongside injectable treatments for prevention.

The available information does not say what happens next.

1 source

Related